# AtaiBeckley Inc. Showcases Breakthrough Findings on BPL-003 for Treatment-Resistant Depression at ACNP Annual Meeting | ATAI Stock News

- URL: https://theranews.net/blog/2026-04-26-ataibeckley-inc-showcases-breakthrough-findings-on-bpl-003-for-treatment-resista-1ad027/
- Published: 2026-04-26
- Type: Archive summary (AI-assisted summary of third-party reporting)
- Original outlet: Quiver Quantitative
- Original report: https://www.quiverquant.com/news/AtaiBeckley+Inc.+Showcases+Breakthrough+Findings+on+BPL-003+for+Treatment-Resistant+Depression+at+ACNP+Annual+Meeting
- Topics: depression
- Publisher: TheraNews, operated by AdvancedCare USA Inc.
- Notice: Educational content, not medical, legal, billing or financial advice. Cite the original outlet, not this summary.

> AtaiBeckley Inc. presented promising clinical data on BPL-003 for treatment-resistant depression at the American College of Neuropsychopharmacology annual meeting, with results recognized as a Hot…

---
AtaiBeckley Inc. presented promising clinical data on BPL-003 for treatment-resistant depression at the American College of Neuropsychopharmacology annual meeting, with results recognized as a Hot Topic at the prestigious conference. The Phase 2b study findings showed that a single 8 mg or 12 mg dose resulted in significant, rapid and sustained antidepressant effects compared with a control group.

## Study Findings

Dr. David Feifel presented efficacy and safety data from the Phase 2b study of BPL-003 nasal spray in patients with treatment-resistant depression. Results showed significant, rapid and sustained antidepressant effects at all timepoints in the study, with both active dose levels well-tolerated. The findings indicate potential benefits of intranasal BPL-003 and highlight the need for further investigation in Phase 3 trials.

## About BPL-003

BPL-003 is a patent-protected intranasal formulation of mebufotenin benzoate being studied for treatment-resistant depression and alcohol use disorder. The drug has been granted Breakthrough Therapy designation by the FDA and is covered by granted US, UK and European composition-of-matter patents. AtaiBeckley also presented preclinical findings on 5-MeO-DMT, with Dr. Michelle Kokkinou sharing data suggesting its therapeutic potential for mood disorders.

## Company Context

AtaiBeckley was formed through the strategic combination of atai Life Sciences and Beckley Psytech Limited in November 2025. The company's pipeline includes VLS-01 (DMT buccal film) for treatment-resistant depression and EMP-01 (oral R-MDMA) for social anxiety disorder, both in Phase 2 clinical development. The company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and treatment-resistant depression.

---

*This article is an AI-assisted summary. All facts and figures are drawn from the original report: [https://www.quiverquant.com/news/AtaiBeckley+Inc.+Showcases+Breakthrough+Findings+on+BPL-003+for+Treatment-Resistant+Depression+at+ACNP+Annual+Meeting](https://www.quiverquant.com/news/AtaiBeckley+Inc.+Showcases+Breakthrough+Findings+on+BPL-003+for+Treatment-Resistant+Depression+at+ACNP+Annual+Meeting)*